PRESS RELEASE
News
-
-
PRESS RELEASE
Oxurion sécurise un financement ferme de 30 millions d'euros dédié à des investissements dans les actifs numériques et crypto actifs
Oxurion NV annonce un financement de 30 millions d'euros avec Atlas Capital Markets pour investir dans les actifs numériques. Accord en obligations convertibles -
PRESS RELEASE
Oxurion secures a binding EUR 30 million financing facility dedicated to investments in digital and crypto assets
Oxurion NV secures €30 million financing via convertible bonds from Atlas Capital Markets to invest in digital assets like Bitcoin and Ethereum. The strategy aligns with the company's long-term investment policy -
PRESS RELEASE
DÉKUPLE ENREGISTRE UNE CROISSANCE SOUTENUE ET CONFIRME LA FORCE DE SON MODÈLE INTÉGRÉ SUR LES 9 MOIS 2025, PORTÉE PAR LE MARKETING DIGITAL ET L’INTERNATIONAL
Le Groupe DÉKUPLE enregistre une croissance soutenue sur les 9 premiers mois 2025, portée par le marketing digital et l'international. Chiffre d'affaires : 175,1 M€ (+12,7 %), revenu net : 130,9 M€ (+7,6 %) -
PRESS RELEASE
DÉKUPLE REPORTS SUSTAINED GROWTH AND CONFIRMS THE STRENGTH OF ITS INTEGRATED MODEL OVER THE FIRST NINE MONTHS OF 2025, DRIVEN BY DIGITAL MARKETING AND INTERNATIONAL EXPANSION
DÉKUPLE reports sustained growth in the first nine months of 2025 driven by digital marketing and international expansion. Net sales up 12.7%, digital marketing key driver -
PRESS RELEASE
Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity
Xlife Sciences AG and saniva diagnostics GmbH announce NeuroMex, the world's first certified medical device for early Alzheimer's detection, with 83.5% accuracy in identifying early-stage Alzheimer's -
-
-
-
PRESS RELEASE
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment options for cancer-related bone disease and osteoporosis. The European launch marks a key milestone in Sandoz's growth strategy
